Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

09.04.24 05:38 Uhr

Werte in diesem Artikel

121,00 EUR 0,00 EUR 0,00%

167,60 EUR -2,25 EUR -1,32%




1.615,0 PKT 1,5 PKT 0,09%

18.693,4 PKT 2,1 PKT 0,01%

7.195,0 PKT -0,7 PKT -0,01%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

189,8 PKT 0,7 PKT 0,38%

39.069,6 PKT 4,3 PKT 0,01%

521,8 PKT -0,2 PKT -0,04%

9.961,4 PKT 0,9 PKT 0,01%

18.700,0 PKT 115,0 PKT 0,62%

18.679,1 PKT 65,3 PKT 0,35%

15.248,7 PKT -196,7 PKT -1,27%

7.362,9 PKT 0,2 PKT 0,00%

16.939,8 PKT 9,0 PKT 0,05%

2.533,1 PKT 17,9 PKT 0,71%

5.304,7 PKT 36,9 PKT 0,70%

18.701,0 PKT 107,4 PKT 0,58%

Merck MRK announced that a phase II/III study has been initiated on its CDH6-directed DXd antibody-drug conjugate, raludotatug deruxtecan (R-DXd), in patients with platinum-resistant ovarian cancer. The first patient has been dosed in the phase II/III study called REJOICE-Ovarian01. Merck is developing R-DXd in partnership with Japan’s Daiichi Sankyo.The initiation of the REJOICE-Ovarian01 study is based on data from the ongoing phase I study in which R-DXd showed promising activity in patients with advanced ovarian cancer. The REJOICE-Ovarian01 study will evaluate the efficacy of R-DXd versus investigator’s choice of chemotherapy.Merck’s stock has risen 16.1% in the past year compared with an increase of 21.5% for the industry. Image Source: Zacks Investment Research Merck acquired global co-development and co-commercialization rights to raludotatug deruxtecan and two other antibody-drug conjugates or ADCs, patritumab deruxtecan/MK-1022 and ifinatamab deruxtecan/MK-2400 from Daiichi Sankyo in October last year. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.Patritumab deruxtecan, a HER3-directed ADC, is under priority review in the United States for previously treated locally advanced or metastatic EGFR-mutated NSCLC. The FDA’s decision is expected on Jun 26, 2024. Ifinatamab deruxtecan is in phase II for small-cell lung cancer.For the deal, Merck made an upfront payment of $4 billion to Daiichi while being entitled to make $1.5 billion in continued payments over 24 months from October 2023. The deal also includes potential sales-based milestone payments of up to $16.5 billion. ADCs are being considered a disruptive innovation in the pharmaceutical industry as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.Daiichi Sankyo has six ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC for HER2-mutated breast, lung and gastric cancers, in partnership with AstraZeneca AZN. Daiichi Sankyo and AstraZeneca have also developed datopotamab deruxtecan (Dato-DXd), a TROP2-directed ADC. Dato-DXd is under FDA review for advanced nonsquamous NSCLC as well as previously treated metastatic HR-positive, HER2-negative breast cancer. The sixth ADC candidate is DS-3939, a TA-MUC1-directed ADC, which Daiichi Sankyo is developing on its own.Zacks Rank & Stocks to ConsiderMerck has a Zacks Rank #3 (Hold) currently.Merck & Co., Inc. Price and Consensus Merck & Co., Inc. price-consensus-chart | Merck & Co., Inc. QuoteSome better-ranked biotech stocks are ADMA Biologics ADMA and MorphoSys MOR, sporting a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Estimates for 2025 have increased from 32 cents to 50 cents. In the past year, shares of ADMA Biologics have risen 100%.Earnings of ADMA Biologics beat estimates in three of the last four quarters while meeting the same once. ADMA delivered a four-quarter average earnings surprise of 85.0%.In the past 60 days, estimates for MorphoSys’ 2024 loss per share have narrowed from $2.24 to $2.08. Estimates for 2025 have narrowed from a loss of $1.02 per share to a loss of 89 cents per share. In the past year, shares of MOR have risen 294.4%.(We are reissuing this article to correct a mistake. The original article, issued on April 4, 2024, should no longer be relied upon.)5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report ADMA Biologics Inc (ADMA): Free Stock Analysis Report MorphoSys AG Unsponsored ADR (MOR): Free Stock Analysis ReportTo read this article on click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Merck

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Merck


Quelle: Zacks

Nachrichten zu Merck KGaA

Analysen zu Merck KGaA

23.05.2024Merck BuyUBS AG
16.05.2024Merck KaufenDZ BANK
16.05.2024Merck OverweightBarclays Capital
15.05.2024Merck BuyUBS AG
08.05.2024Merck BuyUBS AG
23.05.2024Merck BuyUBS AG
16.05.2024Merck KaufenDZ BANK
16.05.2024Merck OverweightBarclays Capital
15.05.2024Merck BuyUBS AG
08.05.2024Merck BuyUBS AG
06.12.2023Merck HaltenDZ BANK
27.11.2023Merck HaltenDZ BANK
27.04.2023Merck HaltenDZ BANK
10.11.2022Merck NeutralUBS AG
05.08.2022Merck HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
06.03.2023Merck VerkaufenDZ BANK
02.03.2023Merck SellGoldman Sachs Group Inc.
07.02.2023Merck SellGoldman Sachs Group Inc.
02.02.2023Merck VerkaufenDZ BANK
15.11.2022Merck SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Merck KGaA nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"